New drug tested for Tough-to-Treat kidney cancer
NCT ID NCT06676527
Summary
This study is observing how well the drug vorolanib works and how safe it is for patients with advanced kidney cancer that has spread or cannot be removed by surgery. It involves 39 adults who are receiving vorolanib as their second treatment option. Researchers will track how long patients live without their cancer getting worse and compare results to data from a previous clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital
RECRUITINGNanjing, Jiangsu, 401520, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.